No abstract

The hospital pharmacist can actively cooperate with nutritional support units, given the need to assess the nutritional support administered and to manage potential complications and interactions between nutritional status, drugs and artificial nutrition. The pharmacist also plays a significant role in the prevention and identification of problems related to the administration of drugs via NGT.

La enfermedad del trastorno de déficit de atención e hiperactividad (TADH) es un trastorno crónico que se inicia en la infancia y perdura hasta la edad adulta pudiendo por tanto afectar tanto a niños como adolescentes y adultos.Posee un diagnóstico complejo y son varias las causas que puedan intervenir en la aparición de este trastorno tales como el sexo, la edad, la etapa del desarrollo y el entorno social y cultural.El TADH tiene diferentes manifestaciones clínicas y según esto, al paciente se le indicará un tratamiento no farmacológico, tratamiento farmacológico o la combinación de ambos.El objetivo principal de nuestro trabajo es analizar en el Área de Gestión Sanitaria Sur de Sevilla (AGSSS) a los pacientes actualmente tratados para el TADH con metilfenidato, lisdexanfetamina, guanfacina y atomoxetina.?Ha sido recopilada toda la información del historial clínico de los pacientes que tienen recetados estos cuatro fármacos en nuestra Área, valorando el grado de adecuación de los tratamientos. Para ello se va a seguir el algoritmo de tratamiento para el TADH propuesto por el CADIME 2017.A la vista de los resultados obtenidos concluimos que hay una falta de seguimiento de los pacientes y una prolongación de tratamiento en el tiempo.

Data suggest that in heart transplant patients it may be crucial to achieve tacrolimus levels of at least 8 ng/ml during the first days postsurgery to avoid rejection.

5-Azacitidine might be considered an effective and relatively safe drug, and may have contributed to controlling peripheral cytopenias, improving the quality of life and delaying progression to leukaemia. Additional studies with more patients are needed to support these results.

No abstract

Background Clinical trials of atezolizumab for locally advanced or metastatic urothelial bladder cancer (mUBC) report controversial efficacy data. Moreover, real-world evidence regarding this use is limited. Aim We aimed to evaluate the effectiveness of atezolizumab in a real-world population with mUBC, to explore the effectiveness in relation to certain poor prognostic criteria such as performance status by Eastern Oncology Cooperative Group (ECOG), hemoglobin levels, and liver metastases, and to determine the safety profile of atezolizumab. Methods This multicenter, retrospective real-world study included previously treated mUBC patients who received atezolizumab. The primary endpoint was overall survival (OS). Furthermore, progression-free survival (PFS), the best response reached, and safety data were analyzed. A descriptive analysis was performed, while OS and PFS were estimated using the Kaplan-Meier method. Results 185 patients (84.9% men, median age 69 years) were included. Median PFS was 4.8 months [95% confidence interval (CI) 3.6-6.0], and median OS was 20.0 months (95% CI 11.8–28.5), with an objective response rate of 28.1%. OS was higher for patients with ECOG 0–1 [24.5 months (95% CI 14.5–34.6) vs 5.2 (95% CI 4.4-6.0), p = 0.004]; and for patients without liver metastases [25.4 months (95% CI 16.2–34.6) vs 6.4 months (95% CI 4.0-8.1), p = 0.006]. Regarding hemoglobin levels, no survival differences were detected. Adverse events were reported in 55.1% of patients. Conclusion In a real-world population with previously treated mUBC, atezolizumab appears to provide a clinically relevant benefit, which is even greater for patients with ECOG 0–1 and those without liver metastases, maintaining an acceptable safety profile.

No abstract